In partnership with QIAGEN®, Ellume has accelerated the development of two rapid, reliable COVID-19 tests to support the global response to the coronavirus pandemic.
The QIAreach™Anti-SARS-CoV-2 Total Test, is a high-performance serological test which detects antibodies in people who have been exposed to SARS-CoV-2. The test was submitted for US FDA Emergency Use Authorization (EUA) in August 2020.
The QIAreach™ Anti-SARS-CoV-2 Antigen Test detects SARS-CoV-2 antigens in people with active infections. QIAGEN has applied for US FDA Emergency Use Authorization and will seek CE-IVD registration in Europe.
Key Features
- Early positive results from 3 minutes
- Simple testing process
- Minimal training requirements
- Single patient visit
- Objective automated test result
- No device calibration or maintenance required
- No cold chain required
- No continuous power supply required
- No computer access required
Coronavirus: The Facts
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. COVID-19 is a respiratory illness primarily spread from person to person. COVID-19 symptoms can range from mild (or no symptoms) to severe illness. There are currently more than 21 million* confirmed cases globally with >775,000 deaths*. With no specific vaccines or treatments currently available for COVID-19, rapid diagnosis is pivotal to minimising transmission.
* Last update: 20 August 2020 – https://www.who.int/emergencies/diseases/novel-coronavirus-2019